What Are the Side Effects of CJC-1295 and Ipamorelin?

What side effects are associated with CJC-1295 and ipamorelin?

Quick answer

The clearest human safety signal for CJC-1295 is temporary injection-site pain, swelling, or firmness. Ipamorelin did not significantly increase ACTH or cortisol in the cited pharmacology study. Because both can raise growth hormone and IGF-1, fluid retention, joint discomfort, and changes in glucose handling are possible pathway-related concerns, but their frequency is not established for the combination.

Reviewed by Taylor Anderson, RN · Aesthetic Registered Nurse · Updated September 2, 2026

Key takeaways

Temporary injection-site pain, swelling, and firmness were the clearest effects reported in human CJC-1295 research.
The cited ipamorelin study found no significant ACTH or cortisol release, and no significant changes in FSH, LH, prolactin, or TSH.
Fluid retention, joint discomfort, and reduced insulin sensitivity are possible growth hormone and IGF-1 pathway effects, not proven incidence rates for both peptides.
The CJC-1295 human studies involved specific research formulations, so their results do not automatically apply to modified GRF (1-29), other products, or combined use.
A clinician should review the formulation, treatment length, symptoms, and glucose history before you decide what fits your goals.

If you are considering CJC-1295 or ipamorelin for energy, libido, or hormone support, start with the effects that have the clearest human data: injection-site pain, swelling, or firmness. Because these compounds stimulate growth hormone and can raise IGF-1, fluid retention, joint discomfort, and changes in glucose handling also deserve attention. The evidence depends on the formulation, dose, treatment length, and whether the peptides are used together. Details checked September 2, 2026.

Women looking for steadier energy, stronger libido, or better hormone support often come across growth hormone secretagogues such as CJC-1295 and ipamorelin. The useful question is which effects were observed directly in human studies and which come from the broader growth hormone and IGF-1 pathway.

The side effects to watch first

The available research points to four separate signals rather than one universal side-effect list.

Effect or signal	Evidence type	How to interpret it
Injection-site pain, swelling, or firmness	Direct human CJC-1295 with DAC evidence	The clearest short-term CJC-1295 signal in the cited research.
Fluid retention or joint discomfort	Growth hormone and IGF-1 pathway evidence	Possible pathway-related effects, not a CJC-1295 or ipamorelin incidence rate.
Glucose changes or reduced insulin sensitivity	Broader growth hormone secretagogue literature	Worth discussing if you monitor glucose, but not specific evidence for both peptides.
ACTH or cortisol changes	Direct ipamorelin pharmacology study	No significant ACTH or cortisol release appeared in that study.

The cited research most clearly supports local reactions with CJC-1295 and selective endocrine activity with ipamorelin. It does not establish that either compound is free of side effects. Keep observed reactions separate from possible growth hormone pathway effects and from findings involving other secretagogues. The primary CJC-1295 trial is available through PubMed, and the ipamorelin pharmacology study is also indexed by PubMed.

What human studies reported about CJC-1295

The main human CJC-1295 data come from two randomized, placebo-controlled, ascending-dose trials in healthy adults ages 21 to 61. The trials lasted 28 and 49 days. After one injection, average growth hormone levels rose for six days or longer, while average IGF-1 levels rose for about nine to 11 days. With repeated dosing, average IGF-1 remained above baseline for up to 28 days. The study reported no serious adverse reactions.

A safety summary of CJC-1295 with DAC identifies temporary injection-site pain, swelling, and firmness as the most frequent adverse events in that healthy-adult research. Those local reactions are the clearest compound-specific signal in the cited material. The same study also shows why treatment length and exposure matter: this is a long-acting formulation with sustained hormone changes.

The trial does not define the risk of every CJC-1295 product. CJC-1295 with DAC and modified GRF (1-29), sometimes described as CJC-1295 without DAC, have different exposure patterns. The FDA docket describes them as separate forms, so results from the long-acting human study should not be treated as interchangeable with every formulation.

Ipamorelin can be selective without being side-effect-free

Ipamorelin is a pentapeptide that activates the ghrelin or GHSR-1a pathway to stimulate growth hormone release. In the cited pharmacology study, it did not produce significant ACTH or cortisol release, unlike GHRP-6 and GHRP-2. The study also found no significant effects on FSH, LH, prolactin, or TSH across the secretagogues tested.

That is useful information about ipamorelin's acute hormonal selectivity. It is not a long-term safety study of CJC-1295 and ipamorelin together. The research focused on immediate hormone responses, while combined use can involve different exposure patterns and downstream growth hormone and IGF-1 effects. A review in PMC discusses how ipamorelin activates the GHSR-1a pathway.

How growth hormone and IGF-1 effects may feel

Some symptoms may come from the hormone pathway rather than from a direct local reaction to one peptide. A review of growth hormone secretagogues discusses fluid retention, musculoskeletal or joint discomfort, changes in glucose handling, reduced insulin sensitivity, appetite changes, fatigue, and insomnia across the wider literature. These findings provide context for what to monitor, not a precise rate for CJC-1295 or ipamorelin.

A 395-adult trial of an oral growth hormone secretagogue reported fatigue and insomnia among its adverse events. That was a different compound, so the result cannot be transferred directly to CJC-1295 or ipamorelin. Likewise, broader growth hormone research can help explain why glucose changes matter without proving how often they occur with this pair.

If you already monitor blood sugar or have a history that makes glucose control a concern, include that information in your clinical discussion. The growth hormone secretagogue safety review explains the broader pathway findings.

Questions to ask before you decide

The compound name alone is not enough to predict your experience. Ask:

Question	Why it matters
Which CJC-1295 form is being discussed?	CJC-1295 with DAC and modified GRF (1-29) are different evidence categories, and the cited human data involve specific research formulations.
What symptoms should you track?	Pay attention to injection-site changes, swelling, joint discomfort, glucose changes, and meaningful shifts in sleep or energy.
Does your glucose history matter?	Possible effects on insulin sensitivity deserve more discussion if you already monitor blood sugar or have a relevant health history.
Is there evidence for using both together?	The cited studies do not establish a direct adverse-event profile for the CJC-1295 and ipamorelin combination.
When should you seek help?	Ask a clinician about persistent or worsening injection reactions, significant swelling or joint symptoms, new glucose changes, or other concerning symptoms.

CJC-1295 research shows that formulation and repeated dosing can produce prolonged IGF-1 elevation. That makes the exact product, treatment length, health background, and combination plan more useful than a generic side-effect checklist.

Current prescribing and compounding requirements can change by product and location. If legality or availability is part of your decision, see the 2026 FDA peptide decision overview and discuss the specific product with a licensed clinician.

Get Hot or Die can review the options with you

Get Hot or Die now prescribes and dispenses medication as a current care option. Its personalized quiz considers your goals, symptoms, and budget, including prescription peptides when clinically appropriate. See what fits your goals and budget.

Key takeaways

Temporary injection-site pain, swelling, and firmness were the clearest effects reported in human CJC-1295 research.
The cited ipamorelin study found no significant ACTH or cortisol release, and no significant changes in FSH, LH, prolactin, or TSH.
Fluid retention, joint discomfort, and reduced insulin sensitivity are possible growth hormone and IGF-1 pathway effects, not proven incidence rates for both peptides.
The CJC-1295 human studies involved specific formulations, so their findings do not automatically apply to modified GRF (1-29), other products, or combined use.
A clinician should review the formulation, treatment length, symptoms, and glucose history before you decide what fits your goals.

Frequently asked questions

What are the most common side effects of CJC-1295?

In the cited human research, temporary injection-site pain, swelling, and firmness were the clearest reported effects. A randomized study reported no serious adverse reactions, but it did not establish the risk of every formulation or regimen.

Does ipamorelin raise cortisol or ACTH?

The cited ipamorelin pharmacology study found no significant ACTH or cortisol release. That result describes the study conditions and does not guarantee the same response with every dose, formulation, or combination.

Can CJC-1295 or ipamorelin affect blood sugar?

Growth hormone signaling can reduce insulin sensitivity and affect glucose handling. The available glucose findings come mainly from broader secretagogue research, so they do not provide a specific rate for CJC-1295 or ipamorelin.

Can CJC-1295 and ipamorelin cause fatigue or insomnia?

Fatigue and insomnia were reported in a trial of a different oral growth hormone secretagogue. That does not establish their frequency or cause with CJC-1295 or ipamorelin, but persistent changes deserve clinical review.

Do CJC-1295 and ipamorelin increase libido or testosterone?

The cited evidence does not establish a predictable libido or testosterone benefit. The ipamorelin pharmacology study found no significant changes in FSH, LH, prolactin, or TSH across the secretagogues tested.

Sources

Ready to make a move?

Answer three questions to see the options, prices, and providers that fit your goals.

See My Plan

Questions women actually ask